Details for New Drug Application (NDA): 020059
✉ Email this page to a colleague
The generic ingredient in ADENOSCAN is adenosine. There are twenty-six drug master file entries for this compound. Additional details are available on the adenosine profile page.
Medical Subject Heading (MeSH) Categories for 020059
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 60MG/20ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | May 18, 1995 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 90MG/30ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | May 18, 1995 | TE: | RLD: | Yes |
Expired US Patents for NDA 020059
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astellas | ADENOSCAN | adenosine | SOLUTION;INTRAVENOUS | 020059-001 | May 18, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Astellas | ADENOSCAN | adenosine | SOLUTION;INTRAVENOUS | 020059-002 | May 18, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Astellas | ADENOSCAN | adenosine | SOLUTION;INTRAVENOUS | 020059-001 | May 18, 1995 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription